
Johannes Czernin MD
Professor, Molecular & Medical Pharmacology, UCLA School of Medicine Chief of the Ahmanson Translational Imaging Division at UCLA
Join to View Full Profile
10833 Le Conte AveLos Angeles, CA 90095
Phone+1 310-301-6800
Fax+1 310-267-0227
Dr. Czernin is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
- UCLA David Geffen School of Medicine/UCLA Medical CenterResidency, Nuclear Medicine, 1994 - 1995
- University of Vienna Faculty of MedicineClass of 1983
Certifications & Licensure
- CA State Medical License 1996 - 2026
- American Board of Nuclear Medicine Nuclear Medicine
Awards, Honors, & Recognition
- Los Angeles Magazine Top Doctors 2018
Clinical Trials
- PET Scan Combined With CT Scan in Evaluating Treatment Response in Patients Undergoing Treatment for Bone Cancer or Soft Tissue Sarcoma Start of enrollment: 2006 Jan 01
- Fluorine F 18 FEQA in Patients With Stage III or Stage IV Non-Small Cell Lung Cancer and in Healthy Participants Start of enrollment: 2004 May 04
- Glucose Metabolism in Patients With Non-Small Cell Lung Cancer Treated With Targeted Therapy and Chemotherapy Start of enrollment: 2004 Dec 01
- Join now to see all
Publications & Presentations
PubMed
- SPARC: The Standardised Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography Analysis and Reporting Consensus: A Delphi Analysis.Ken Herrmann, Jochen Walz, Steven MacLennan, Alberto Briganti, Philip Cornford
European Urology. 2025-09-12 - Precision Medicine Is Critical for the Future of Oncology: Johannes Czernin and Ken Herrmann Talk with Chris Behrenbruch on Theranostics, Imaging, and the Urgency to I...Christian Behrenbruch, Ken Herrmann, Johannes Czernin
Journal of Nuclear Medicine. 2025-09-02 - Randomized Phase 2 Trial of an Extended and Flexible Dosing Schedule ofLu-PSMA Molecular Radiotherapy in Patients with Metastatic Castration-Resistant Prostate Cancer ...Adrien Holzgreve, Astrid Delker, Zachary Ells, Julia Brosch-Lenz, Lena M Unterrainer
Journal of Nuclear Medicine. 2025-08-28
Press Mentions
- Legacy of Theranostics Innovation Transforms Cancer CareJanuary 15th, 2025
- JNM Maintains Strong Metrics in 2023 Journal Citation ReportsJuly 24th, 2024
- UCLA Researchers Receive Grant from Prostate Cancer FoundationDecember 14th, 2022
- Join now to see all
Grant Support
- Multidimensional analyses to improve PSMA-RPT efficacy in mCRPCUNIVERSITY OF CALIFORNIA LOS ANGELES2023–2028
Other Languages
- German
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: